Abstract
Background:
Oxaliplatin use in gastrointestinal malignancies is limited by neurotoxicity. This study aimed to assess the efficacy of pregabalin (LYRICA(R)) in the treatment of oxaliplatin-induced neurotoxicity.
Patients and methods:
A total of 23 gastrointestinal cancer patients with grade 2 and 3 oxaliplatin-induced sensory neuropathy were treated with pregabalin up to a target dose of 150mg orally (PO) three times a day (tid) based on benefit and tolerance. Neurological symptoms were serially evaluated.
Results:
The target dose of 150 mg tid provided the best benefit, but patients benefited even at lower doses. Onset of benefit was observed in 2-6 weeks. In the majority of patients (48%), neuropathy improved by 1 to 2 grades.
Conclusion:
Pregabalin significantly reduced the severity of oxaliplatin-induced sensory neuropathy. Being more potent than gabapentin, pregabalin achieved efficacy at lower doses and should lead to fewer dose-related side effects, although this remains to be established in a head-to-head trial.
MeSH terms
-
Aged
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Capecitabine
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives
-
Dose-Response Relationship, Drug
-
Epirubicin / administration & dosage
-
Epirubicin / adverse effects
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Fluorouracil / analogs & derivatives
-
Gastrointestinal Neoplasms / drug therapy
-
Gemcitabine
-
Humans
-
Male
-
Middle Aged
-
Neurotoxicity Syndromes / drug therapy*
-
Neurotoxicity Syndromes / etiology*
-
Organoplatinum Compounds / administration & dosage
-
Organoplatinum Compounds / adverse effects*
-
Oxaliplatin
-
Pregabalin
-
gamma-Aminobutyric Acid / adverse effects
-
gamma-Aminobutyric Acid / analogs & derivatives*
-
gamma-Aminobutyric Acid / therapeutic use
Substances
-
Antineoplastic Agents
-
Organoplatinum Compounds
-
Oxaliplatin
-
Deoxycytidine
-
Epirubicin
-
Pregabalin
-
gamma-Aminobutyric Acid
-
Capecitabine
-
Fluorouracil
-
Gemcitabine